2023
Phase II trial of pembrolizumab in patients with brain metastases.
Brastianos P, Kim A, Giobbie-Hurder A, Lee E, Lin N, Overmoyer B, Wen P, Nayak L, Cohen J, Dietrich J, Heist R, Krop I, Lawrence D, Mayer E, Winer E, Shih H, Oh K, Cahill D, Gerstner E, Sullivan R. Phase II trial of pembrolizumab in patients with brain metastases. Journal Of Clinical Oncology 2023, 41: 2006-2006. DOI: 10.1200/jco.2023.41.16_suppl.2006.Peer-Reviewed Original ResearchBrain metastasesPrimary endpointBenefit rateEvaluable patientsLung cancerBreast cancerTherapeutic strategiesSingle-arm phase 2 clinical trialNon-small cell lung cancerHormone receptor-positive diseaseSmall cell lung cancerPhase 2 clinical trialGrade 4 toxicityLogical therapeutic strategyRECIST 1.1 criteriaMedian overall survivalPD-1 blockadePD-1 inhibitorsPrimary efficacy endpointReceptor-positive diseasePhase II trialImmune-based strategiesTriple-negative subtypeCell lung cancerT cell cytotoxicity
2021
FOXA1 and adaptive response determinants to HER2 targeted therapy in TBCRC 036
Angus SP, Stuhlmiller TJ, Mehta G, Bevill SM, Goulet DR, Olivares-Quintero JF, East MP, Tanioka M, Zawistowski JS, Singh D, Sciaky N, Chen X, He X, Rashid NU, Chollet-Hinton L, Fan C, Soloway MG, Spears PA, Jefferys S, Parker JS, Gallagher KK, Forero-Torres A, Krop IE, Thompson AM, Murthy R, Gatza ML, Perou CM, Earp HS, Carey LA, Johnson GL. FOXA1 and adaptive response determinants to HER2 targeted therapy in TBCRC 036. Npj Breast Cancer 2021, 7: 51. PMID: 33980863, PMCID: PMC8115531, DOI: 10.1038/s41523-021-00258-0.Peer-Reviewed Original ResearchHER2/ErbB2 receptorGene signatureAnti-HER2 monoclonal antibodyHER2-positive malignanciesImmune gene signaturesAnti-HER2 therapyHER2-positive breastPotential therapeutic strategyAnti-HER2 antibodyFOXA1 depletionHER3 levelsProliferation gene signatureClinical trialsPharmacodynamic responseBreast cancerImmune responseTherapeutic strategiesFOXA1 expressionTranscription factor FOXA1Cell line responseHER2Adaptive responseMonoclonal antibodiesAdaptive upregulationLapatinib